Macular Edema and Macular Degeneration Market Report 2026

Macular Edema and Macular Degeneration Market Overview

• Macular Edema and Macular Degeneration market size has reached to $10.33 billion in 2025 • Expected to grow to $14.33 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Elevated Diabetes Prevalence Fuels Growth In The Macular Edema And Macular Degeneration Market • Market Trend: Next-Generation Solutions for Chronic Eye Conditions Transforming Standard Care Practices • North America was the largest region in 2025.

What Is Covered Under Macular Edema and Macular Degeneration Market?

Macular edema and macular degeneration are two different eye conditions that can affect vision. Macular edema is swelling in the part of the retina at the back of the eye, which can cause blurry vision. Macular degeneration is a condition that affects the macula, a part of the retina at the back of the eye that is responsible for central vision. They can be caused by many different conditions, including diabetic retinopathy, retinal vein occlusion, and inflammation, and include age, genetics, smoking, high blood pressure, and obesity. The main types of macular edema and macular degeneration treatment include drug therapy and laser treatment. Drug therapy refers to the use of pharmaceutical drugs or medications to treat, manage, or alleviate medical conditions, diseases, or symptoms in individuals. It is used for various applications including macular edema, diabetic macular edema (DME), cystoid macular edema (CME), macular degeneration, dry age-related macular degeneration, and wet age-related macular degeneration by hospitals, clinics, and other end users.

What Is The Macular Edema and Macular Degeneration Market Growth Forecast?

The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $14.33 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising global diabetic population, increasing screening for retinal diseases, growing demand for minimally invasive eye treatments, expanding access to advanced ophthalmic care, higher healthcare spending on vision preservation. Major trends in the forecast period include rising adoption of anti-vegf based therapies, growing demand for early diagnosis and intervention, increasing use of combination drug and laser therapies, rising focus on managing diabetic eye complications, expansion of outpatient and clinic-based eye care.

Global Macular Edema and Macular Degeneration Market Segmentation

1) By Treatment Type: Drug Therapy, Laser Treatment 2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration 3) By End User: Hospitals, Clinics, Other End Users Subsegments: 1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Combination Therapy (Anti-VEGF + Steroids) 2) By Laser Treatment: Focal Laser Photocoagulation, Subthreshold Laser Therapy, MicroPulse Laser Therapy

What Is The Driver Of The Macular Edema and Macular Degeneration Market?

The rising diabetes population is expected to propel the growth of the macular edema and macular degeneration market going forward. Diabetes is a chronic medical condition characterized by high glucose (sugar) levels in the blood. Diabetes damages the blood vessels in the eye, which can result in macular edema and macular degeneration. For instance, in June 2024, according to The National Health Service (NHS England), a UK-based publicly funded healthcare system, in 2023, the number of individuals identified by the NHS in England as having pre-diabetes rose to 3,615,330, marking an 18% increase from 3,065,825 in 2022. Additionally, among those under 40, cases surged nearly 25%, growing from 173,166 in 2022 to 216,440 in 2023. Therefore, the rising diabetes population is driving the growth of the macular edema and macular degeneration industry.

Key Players In The Global Macular Edema and Macular Degeneration Market

Major companies operating in the macular edema and macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., Ocugen Inc.

Global Macular Edema and Macular Degeneration Market Trends and Insights

Major companies operating in the macular edema and macular degeneration market are focusing on developing innovative products such as continuous-delivery ocular implants to reduce treatment burden, improve patient adherence, and deliver more consistent long-term therapeutic outcomes. Continuous-delivery ocular implants are small, refillable devices placed in the eye that slowly release medication over several months, helping patients by reducing the need for frequent injections and providing steady, long-term treatment for retinal diseases. For instance, in February 2025, F. Hoffmann-La Roche Ltd, a Switzerland-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for Susvimo, a refillable ocular implant delivering the anti-VEGF drug ranibizumab for the treatment of diabetic macular edema (DME). Susvimo is designed as a long-acting, surgically implanted reservoir that continuously releases a customised formulation of ranibizumab, maintaining therapeutic drug levels for extended durations. Unlike traditional anti-VEGF intravitreal injections that often require monthly or bi-monthly dosing, Susvimo offers a refill-exchange interval of roughly six months, dramatically reducing patient treatment burden. Its sustained-delivery design enhances adherence, streamlines clinical workflow, and provides durable anatomical and visual benefits for patients with chronic retinal disease.

What Are Latest Mergers And Acquisitions In The Macular Edema and Macular Degeneration Market?

In July 2024, Merck And Co. Inc., a US-based pharmaceutical and biotechnology company, acquired Eyebiotech Limited (Eyebio) for an undisclosed amount. The aim of the acquisition is to strengthen and diversify Merck's late-stage pipeline by adding Restoret, a novel late-phase candidate for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). This acquisition enhances MSD's portfolio with innovative treatments based on novel biology and genetics, addressing unmet medical needs in retinal diseases. Eyebiotech Limited (eyebio) is a US-based ophthalmology biotechnology company that develops therapies to treat sight-threatening eye diseases, including macular edema and macular degeneration.

Regional Outlook

North America was the largest region in the macular edema and macular degeneration market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Macular Edema and Macular Degeneration Market?

The macular edema and macular degeneration market consists of revenues earned by entities by providing services such as ophthalmic care, ophthalmologic evaluation, imaging and diagnostics, laser therapy, photodynamic therapy, and rehabilitation and low vision services. The market value includes the value of related goods sold by the service provider or included within the service offering. The macular edema and macular degeneration market also includes sales of surgical interventions, low vision aids, dietary supplements, retinal implants, and subretinal injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Macular Edema and Macular Degeneration Market Report 2026?

The macular edema and macular degeneration market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the macular edema and macular degeneration industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.